Sanofi (NASDAQ:SNY) Given Consensus Recommendation of “Hold” by Analysts

Shares of Sanofi (NASDAQ:SNY) have been given a consensus rating of “Hold” by the fourteen analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $61.50.

Several research analysts have issued reports on SNY shares. Barclays cut shares of Sanofi from an “overweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Guggenheim cut shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Tuesday, December 9th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. UBS Group reissued a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. Finally, Weiss Ratings cut shares of Sanofi from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, March 23rd.

Sanofi Stock Down 0.6%

Shares of Sanofi stock opened at $47.60 on Tuesday. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09. The stock has a market capitalization of $116.10 billion, a PE ratio of 13.22, a price-to-earnings-growth ratio of 1.19 and a beta of 0.42. Sanofi has a 52-week low of $43.32 and a 52-week high of $55.73. The company has a 50-day simple moving average of $46.44 and a two-hundred day simple moving average of $48.02.

Institutional Trading of Sanofi

A number of hedge funds have recently bought and sold shares of SNY. Mondrian Investment Partners LTD purchased a new stake in Sanofi during the third quarter valued at $171,742,000. Raymond James Financial Inc. increased its position in Sanofi by 81.3% during the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after acquiring an additional 2,635,867 shares during the last quarter. Thrivent Financial for Lutherans increased its position in Sanofi by 10,152.1% during the third quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company’s stock valued at $103,846,000 after acquiring an additional 2,178,647 shares during the last quarter. Capital Research Global Investors purchased a new stake in Sanofi during the fourth quarter valued at $79,960,000. Finally, Morgan Stanley increased its position in Sanofi by 20.4% during the fourth quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock valued at $441,093,000 after acquiring an additional 1,540,271 shares during the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.